Cardiac Diseases and Therapies
HEART FAILURE
ACUTE HEART FAILURE

- Refers to new or worsening signs and symptoms of heart failure (HF) that are usually caused by volume overload and/or hypoperfusion
- A relatively equal percentage of patients with acutely decompensated HF have impaired versus preserved LV systolic function
- Precipitating cause(s) for acute HF should be sought for appropriate treatment and to prevent future acute events
- The majority of patients do present with features of congestion/fluid overload on clinical assessment
- Acute HF requiring hospitalization may be a marker of deterioration and worsening prognosis

KEY POINTS

- Oral chronic HF therapy should generally be continued in the absence of hemodynamic instability or contraindications
- Patients admitted with significant worsening of renal function should be considered for a reduction in, or temporary discontinuation of ACE inhibitors, ARBs, and/or mineralocorticoid receptor antagonists until renal function improves
- Continuation of beta-blocker upon admission for acute HF is safe, unless the patient is symptomatic from hypotension or bradycardia
- Routine use of vasodilators and positive inotropes have not been shown to improve survival in hemodynamically stable patients
- Ultrafiltration may be of benefit in relieving congestion particularly in diuretic-resistant patients, but a recent study suggests it may be no more effective than pharmacologic therapy in most patients
- Vasopressin receptor antagonists (e.g. tolvaptan) can rapidly and effectively reduce body weight and restore serum sodium in hyponatremic patients with congestion but their use has not been associated with mortality benefits
- Monitor fluid intake and output, vital signs, body weight, clinical signs and symptoms of systemic perfusion and congestion, and daily serum electrolytes and creatinine
Figure 1. Algorithm for Treatment of Acute Heart Failure

**O₂ Sats ≤ 92%**
- Oxygen ↑FiO₂
- CPAP/BiPAP
- Mechanical intubation

**Volume Overload**
- IV furosemide bolus
  OR
- IV furosemide infusion
  5 to 20 mg/hr

**Consider SBP / MAP**

- **SBP < 90 mm Hg / MAP < 60 mm Hg**
  - Dopamine or other vasopressor
  - Dobutamine

- **SBP = 90-100 mm Hg / MAP = 60-65 mm Hg**
  - If low cardiac output suspected by clinical exam or confirmed with PA catheter, add dobutamine or milrinone

- **SBP > 100 mm Hg / MAP > 65 mm Hg**
  - If not adequately responsive to IV diuretics, consider adding nitroprusside IV or nitroglycerin IV
COMMON FACTORS THAT PRECIPITATE ACUTE DECOMPENSATED HEART FAILURE

- Nonadherence with medication regimen
- Nonadherence with diet (e.g. sodium intake and/or fluid restriction)
- Acute myocardial ischemia
- Uncorrected high blood pressure
- New onset and/or deterioration in atrial fibrillation and other arrhythmias
- Recent addition of negative inotropic drugs (e.g. verapamil, diltiazem, nifedipine, beta-blockers)
- Pulmonary embolus
- Initiation of drugs that increase salt retention (e.g. steroids, thiazolidinediones, NSAIDs)
- Excessive alcohol or illicit drug use (e.g. cocaine, amphetamines)
- Endocrine abnormalities (e.g. diabetes mellitus, hyperthyroidism, hypothyroidism)
- Concurrent infections (e.g. pneumonia, viral illnesses)
- Additional acute cardiovascular disorders (e.g. endocarditis, myopericarditis, aortic dissection)

Figure 2. Classification of Patients Presenting with Acute Decompensated Heart Failure

The clinical goals of pharmacologic therapy include:

- Relieve congestive symptoms or optimize volume status
- Treat symptoms of low cardiac output

PHARMACOLOGIC THERAPY

To relieve congestion:

- Mild volume overload – IV furosemide boluses
- Moderate to severe volume overload
  - Increase IV furosemide bolus dose/frequency
  - Consider furosemide continuous infusion if the nursing unit permits as per the UHN Restricted Nursing IV Drug List
  - Add metolazone/hydrochlorothiazide to furosemide
Add IV vasodilators (nitroprusside or nitroglycerin)

Ultrafiltration may be considered for persistent congestion despite optimized diuretic therapy

**To increase cardiac output:**

- If SBP < 90 mmHg or MAP < 60 mmHg, consider vasopressors and/or dobutamine
- If SBP = 90-100 mmHg or MAP = 60-65 mmHg, consider dobutamine or milrinone
- If SBP > 100 mmHg or MAP > 65 mmHg, consider IV vasodilators (nitroprusside or nitroglycerin)

- ACE inhibitors should not be initiated in the acute setting (e.g. first 8-12 hours) unless elevated BP is present – they should be initiated after the acute event (e.g. > 24 hours)
- Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents. Beta-blocker therapy should be initiated at a low dose and only in stable patients.

**INVASIVE HEMODYNAMIC MONITORING**

Routine use of invasive hemodynamic monitoring with a pulmonary artery (PA) catheter is not recommended in normotensive patients with acute HF and congestion with symptomatic response to diuretics and vasodilators.

PA catheter is, however, useful in the following situations:

- Presumed cardiogenic shock requiring escalating vasopressor therapy and consideration of mechanical circulatory support
- Severe clinical decompensation in which therapy is limited by uncertain contributions of elevated filling pressures, hypoperfusion, and vascular tone
- Apparent dependence on intravenous inotropic infusions after initial clinical improvement
- Persistent severe symptoms despite adjustment of recommended therapies
- To guide therapy in the presence of severe diffuse pulmonary disease
## Cardiac Diseases and Therapies

### HEART FAILURE

#### ACUTE HEART FAILURE

### INOTROPES

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>( t_{1/2} )</th>
<th>Receptor Affinity</th>
<th>Effects</th>
<th>Adverse Effects</th>
</tr>
</thead>
</table>
| Dobutamine | \(<5 \text{ mcg/kg/min}\) | 2-3 min       | \(
\alpha_1\) ++ | \(\beta_1\) ++++ | \(\beta_2\) ++ | \(\text{DA}\) 0 | \(\text{CO}\) ↑ | \(\text{HR}\) ↑ | \(\text{SVR}\) ↓ | \(\text{PVR}\) ↔ | ↑/↓ \(\text{BP}\), headache, tachyarrhythmias, nausea, fever, hypersensitivity, cardiac ischemia |
|            | \(5\text{ to }20 \text{ mcg/kg/min}\) |               |                   |         |                                                      |                  |                  |                  |                  |                                                      |
| Milrinone  | Loading dose (optional): 25 to 50 mcg/kg bolus over 10 min, 0.125 to 0.75 mcg/kg/min | 2.5 h         | N/A (phosphodiesterase inhibitor) | ↑       | ↑         | ↓        | ↓        | tachyarrhythmias, ↓\(\text{BP}\), cardiac ischemia |
| Dopamine   | \(<3 \text{ mcg/kg/min}\) | 2-20 min      | ++++              | ++++    | ++        | ++       | ↑/↔ | ↔       | ↔       | ↔       | tachyarrhythmias, headache, nausea, tissue necrosis, ↑\(\text{BP}\), cardiac ischemia |
|            | \(3\text{ to }10 \text{ mcg/kg/min}\) |               |                   |         |                                                      |                  |                  |                  |                  |                                                      |
|            | \(10\text{ to }20 \text{ mcg/kg/min}\) |               |                   |         |                                                      |                  |                  |                  |                  |                                                      |

\( \text{DA} = \text{dopamine receptors} \)

### VASODILATORS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>( t_{1/2} )</th>
<th>Mechanism of Action</th>
<th>Clinical Response</th>
<th>Hemodynamic Effects</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroprusside</td>
<td>0.25 to 3 mcg/kg/min</td>
<td>2 min</td>
<td>Acts on vascular smooth muscle and increases synthesis of nitric oxide</td>
<td>Mixed arterial-venous vasodilation</td>
<td>( \text{CO} ) ↑</td>
<td>( \text{SVR} ) ↓</td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>5 to 200 mcg/min</td>
<td>1-4 min</td>
<td>Activates guanylate cyclase to ( \uparrow ) cGMP in vascular smooth muscle, by serving as nitric oxide donor</td>
<td>- Venodilation - Mild arterial vasodilation - Coronary vasodilation with beneficial effects on myocardial oxygen demand and supply</td>
<td>( \text{CO} ) ↑/↔</td>
<td>( \text{SVR} ) ↓/↔</td>
</tr>
</tbody>
</table>
DIURETIC DOSING FOR THE TREATMENT OF ACUTE HEART FAILURE

Based on The Diuretic Optimization Strategies Evaluation (DOSE) trial:
- There is no difference between furosemide continuous infusion and intermittent bolus dosing in either symptoms or renal function
- There was a trend towards greater symptom improvement with high compared with low dose diuretics without a significant difference in renal function
- In summary, there is no advantage in the routine use of continuous diuretic infusions and a higher dose of diuretics could be considered, with close observation of renal function and electrolytes

<table>
<thead>
<tr>
<th>Creatinine clearance*</th>
<th>Patient</th>
<th>Initial IV dose**</th>
<th>Maintenance dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥60 mL/min/1.73m²</td>
<td>New-onset HF or no maintenance diuretic therapy</td>
<td>Furosemide 20-40 mg 2-3 times daily</td>
<td>Lowest diuretic dose that allows for diuresis is the ideal dose</td>
</tr>
<tr>
<td></td>
<td>Established HF or chronic oral diuretic therapy</td>
<td>Furosemide bolus same as oral dose 1:1***</td>
<td></td>
</tr>
<tr>
<td>&lt;60 mL/min/1.73m²</td>
<td>New-onset HF or no maintenance diuretic therapy</td>
<td>Furosemide 20-80 mg 2-3 times daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Established HF or chronic oral diuretic therapy</td>
<td>Furosemide bolus same as oral dose 1:1***</td>
<td></td>
</tr>
</tbody>
</table>

*Creatinine clearance is calculated from the Cockroft-Gault or Modified Diet in Renal Disease formula
**Intravenous continuous furosemide at doses of 5 to 20mg/h is also an option.
***Example: if patient was on 40 mg orally, initial IV dose would be 40 mg IV

REFERENCES

Prepared by: Yvonne Kwan BScPhm, ACPR
Last modified: January 27, 2016
Reviewed by: Dr. Michael McDonald
Cardiac Diseases and Therapies

HEART FAILURE

ACUTE HEART FAILURE

Terms and Conditions

Copyright © University Health Network, 2016. All rights reserved.

The contents of this Handbook are approved and endorsed by the UHN Cardiovascular Subcommittee of the Pharmacy and Therapeutics Committee.

1. Purpose of the Pharmacotherapy Handbook.

Notice to Healthcare Providers:

The Pharmacotherapy Handbook is intended to be used as a tool to aid in the appropriate prescribing and administration of cardiovascular formulary agents.

This information in this Handbook is intended for use by and with experienced physicians and pharmacists. The information is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about Cardiovascular illness and the treatments in question.

Due to the rapidly changing nature of cardiovascular treatments and therapies, users are advised to recheck the information contained herein with the original source before applying it to patient care.

Notice to non-Healthcare Providers:

Not Medical Advice. The information contained in the Handbook is not a substitute for professional medical advice, diagnosis or treatment. Never make changes to your medication, nor adjust your dose, without first consulting your health care provider. Always seek the advice of a physician or other qualified healthcare provider concerning questions you have regarding a medical condition, and before starting, stopping or modifying any treatment or medication. Never delay obtaining medical advice or disregard medical advice because of something you have or have not read in the Handbook. If you have, or suspect you have, a health problem, or if you experience an adverse side effect, please consult your doctor. If you have, or suspect you are experiencing a health emergency, please call 911 and/or promptly visit a Hospital Emergency Department in your area.

2. DISCLAIMER: UNIVERSITY HEALTH NETWORK MAKES NO WARRANTIES OR REPRESENTATIONS AS TO THE ACCURACY OF THE INFORMATION PROVIDED. THE INFORMATION CONTAINED IN OR PRESENTED IN THIS HANDBOOK COMES WITHOUT ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED. ANY IMPLIED WARRANTY OR CONDITION OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF NONINFRINGEMENT OF THIRD PARTY RIGHTS, AND FREEDOM FROM COMPUTER VIRUSES, IN RESPECT OF THE HANDBOOK IS EXPRESSLY DISCLAIMED.

3. Disclaimer. Neither UHN, as an entity, nor any of its staff or contractors cannot under any circumstance be held liable for consequences caused by or deriving from the use of the Handbook or any information contained in the Handbook. UHN is not liable for damages arising from use of the Handbook, or from third party websites (via hyperlinks) to which references are made in the Handbook. In no event shall UHN be liable for direct, indirect, consequential, special, exemplary, or other damages related to your use of the Handbook, regardless of how arising or the theory of liability whether arising in contract, tort, negligence or otherwise.

Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites, including but not limited to the terms and conditions of http://pie.med.utoronto.ca/ on which this Handbook is housed.

4. Governing Law and Jurisdiction. Any action or claim arising from or related to your use of the Handbook shall be brought in the courts of, and governed exclusively by, the laws of Ontario, Canada and the applicable laws of Canada applicable therein, without regard to its conflicts of laws principles. Unless prohibited by applicable law, you expressly waive the right to participate in a class action proceeding.

Your comments on the usefulness of the resources contained in the Handbook are welcomed and may be forwarded to Amita Woods, Department of Pharmacy Services (amita.woods@uhn.ca).